dc.creator | Zabana, Yamile | es |
dc.creator | Marín Jiménez, Ignacio | es |
dc.creator | Rodríguez Lago, Iago | es |
dc.creator | Vera, Isabel | es |
dc.creator | Martín Arranz, Maria Dolores | es |
dc.creator | Guerra, Iván | es |
dc.creator | Argüelles Arias, Federico | es |
dc.creator | Esteve, María | es |
dc.date.accessioned | 2022-09-28T13:58:27Z | |
dc.date.available | 2022-09-28T13:58:27Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Zabana, Y., Marín Jiménez, I., Rodríguez Lago, I., Vera, I., Martín Arranz, M.D., Guerra, I.,...,Esteve, M. (2022). Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. Journal of Clinical Medicine, 11 (2), 1-20. | |
dc.identifier.issn | 2077-0383 | es |
dc.identifier.uri | https://hdl.handle.net/11441/137433 | |
dc.description.abstract | We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March–July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8–27 and 4.5, 95% CI: 1.3–15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3–11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. | es |
dc.format | application/pdf | es |
dc.format.extent | 20 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Journal of Clinical Medicine, 11 (2), 1-20. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Covid-19 | es |
dc.subject | SARS-CoV-2 | es |
dc.subject | Inflammatory bowel disease | es |
dc.title | Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.mdpi.com/2077-0383/11/2/421 | es |
dc.identifier.doi | 10.3390/jcm11020421 | es |
dc.journaltitle | Journal of Clinical Medicine | es |
dc.publication.volumen | 11 | es |
dc.publication.issue | 2 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 20 | es |